Codexis, Inc. CDXS 深 沪
已收盘 02-06 16:00:00 美东时间
1.33
+0.060
+4.72%
华盛通- 最 高1.36
- 今 开1.30
- 成交量 120.22万股
- 最 低 1.27
- 昨 收 1.27
- 总市值 1.20亿
- 52周最高 4.46
- 市盈率 静 --
- 换手率 1.33%
- 52周最低 1.22
- 委 比 72.50%
- 总股本 9032.44万
- 历史最高 42.01
- 量 比 0.86
- 振 幅 7.09%
- 历史最低 1.22
- 每 手 1
- 风险率 0.65%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Codexis Announces Signing of Lease for GMP Manufacturing Facility
Codexis leased a 34,000 sq. ft GMP facility in Hayward, California, expanding its manufacturing capabilities for drug substances using the ECO Synthesis platform. Starting early 2026, the facility will produce oligonucleotides and support early-clinical trials through enhanced quality and service flexibility.
2025-11-10 14:00
Codexis shares are trading lower after the company reported worse-than-expected Q3 financial results.
Codexis shares are trading lower after the company reported worse-than-expected...
2025-11-07 06:05
In October, Codexis Announces Signing Of $37.8M Supply Assurance Agreement with Merck, Reduced Around 24% Of Its Workforce
As of September 30, 2025, the Company had $58.7 million in cash, cash equivalents and short-term investments.In November 2025, Codexis eliminated 46 positions, or approximately 24% of its workforce. The company expects
2025-11-07 05:50
Codexis to Participate in Cantor Global Healthcare Conference
Codexis, Inc. (NASDAQ: CDXS) announced its participation in the Cantor Global Healthcare Conference in New York from September 3-5, 2025. Management will engage in a fireside chat on September 4 at 3:55 pm ET, with a live webcast available on the Company’s Investor Relations website and a 90-day replay. Codexis leverages its proprietary CodeEvolver® technology to develop high-performance enzymes for efficient therapeutics manufacturing.
2025-08-28 13:00
Codexis shares are trading higher after the company reported better-than-expected Q2 financial results.
Codexis shares are trading higher after the company reported better-than-expect...
2025-08-14 20:38
Codexis reiterates $64M–$68M 2025 revenue guidance while exploring ECO Synthesis expansion
Earnings Call Insights: Codexis (CDXS) Q2 2025 Management View Stephen George Dilly, President, CEO & Chairman, stated the second quarter results were strong, highlighting that "our revenue is above c...
2025-08-14 07:59
Codexis Q2 EPS $(0.16) Beats $(0.19) Estimate, Sales $15.33M Beat $14.11M Estimate
Codexis (NASDAQ:CDXS) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.19) by 15.34 percent. This is a 50 percent increase over losses of $(0.32) per share from the same
2025-08-14 04:07
Earnings Scheduled For August 13, 2025
Companies Reporting Before The Bell • Evotec (NASDAQ:EVO) is projected to repor...
2025-08-13 16:32
Codexis to Report Second Quarter 2025 Financial Results on August 13
Codexis, Inc. announced it will report its Q2 2025 financial results on August 13, 2025, after market close. A conference call and webcast discussing the results will be held at 4:30 pm Eastern Time. The live webcast will be available on Codexis' Investor Relations website, along with a 90-day archive. Call-in details are provided for domestic and international participants, including replay access. Codexis specializes in enzymatic solutions for ...
2025-07-30 20:05
